AstraZeneca Plc reported double-digit revenue growth for the second quarter and first half year driven by several oncology medicines and by Farxiga, a diabetes drug recently approved in the US for chronic kidney disease. On 21 July, the company also completed the acquisition of Alexion Pharmaceuticals for $39 billion – a deal that will give it a rare disease portfolio and strengthen group revenue going forward. Alexion’s technology is based on complement biology.
